Brief: AC Immune - Full Week-100 Results From Part 1 VacSYn Trial Expected In H2 2026
11/08/2026 12:44
BRIEF-AC Immune - Full Week-100 Results From Part 1 VacSYn Trial Expected In H2 2026 Aug 11 (Reuters) - AC Immune SA ACIU.O:
AC IMMUNE RECEIVES FDA FAST TRACK DESIGNATION FOR ANTI-ALPHA-SYNUCLEIN ACTIVE IMMUNOTHERAPY, ACI-7104, TO TREAT EARLY PARKINSON’S DISEASE (PD)
AC IMMUNE - FULL WEEK-100 RESULTS FROM PART 1 VACSYN TRIAL EXPECTED IN H2 2026
AC IMMUNE - INTERIM RESULTS SHOW SAFETY AND IMMUNOGENICITY WITH EARLY SIGNALS OF ACTIVITY FOR ACI-7104
Source text: ID:nGNXc2Ynp5
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune AG
See all newsAC Immune rises after Parkinson's drug shows promise in mid-stage trial
Brief: Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health